Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Trevi Therapeutics, Inc.’s reported figures.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
FAQ
- What is Trevi Therapeutics, Inc.'s EBITDA?
- Trevi Therapeutics, Inc. (TRVI) reported EBITDA of -$14.88M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s EBITDA changed year-over-year?
- Trevi Therapeutics, Inc.'s EBITDA decreased by 30.1% year-over-year, from -$11.43M to -$14.88M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s EBITDA has grown at a 11.0% compound annual growth rate (CAGR), from -$32.43M to -$49.18M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Trevi Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude